Pharmaceuticals
NanoViricides Highlights Broad-Spectrum Antiviral Candidate After Andes Hantavirus Incident on Cruise Ship
NanoViricides points to its clinical-stage antiviral candidate NV-387 as a potential broad-spectrum therapeutic following an Andes hantavirus incident aboard a cruise ship, underscoring the need for versatile antiviral treatments.
Kairos Pharma Sets Virtual Annual Meeting, Discloses Going Concern Notice
Kairos Pharma announced its virtual annual meeting and disclosed a going concern notice in its 2025 annual report, highlighting financial uncertainties for the clinical-stage biopharmaceutical company.
Oncotelic Therapeutics Targets CNS Drug Delivery as Brain Therapeutics Innovation Accelerates
Oncotelic Therapeutics is leveraging its intranasal nose-to-brain delivery platform to address the challenge of delivering therapeutics across the blood-brain barrier, targeting Alzheimer's disease and biodefense applications in a rapidly evolving biopharma landscape.
SureNano Science Advances GEP-44 as Obesity Drug Market Poised to Exceed $200 Billion
SureNano Science Ltd., through its subsidiary GlucaPharm Inc., is developing GEP-44, a next-generation GLP-1 triple agonist peptide targeting obesity and metabolic disorders, as the global market for such therapies is projected to surpass $200 billion.
SureNano Science Advances Next-Generation GLP-1 Platform with Triple Agonist Peptide GEP-44
SureNano Science Ltd. is developing GEP-44, a novel triple agonist peptide for improved GLP-1 therapy, aiming to address obesity and diabetes alongside major players like Eli Lilly and Novo Nordisk.
CNS Drug Delivery Innovations Address Critical Bottleneck in Biotech Market
Advancements in blood-brain barrier penetration technologies, such as Oncotelic's intranasal nose-to-brain system, are unlocking significant opportunities in the biotech sector by enabling targeted CNS therapies for diseases like Alzheimer's and bolstering biodefense preparedness.
Silo Pharma Launches Ibogaine-Based TBI Therapeutics Initiative
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provisional patent application.
NanoViricides to Present at D. Boral Capital Global Conference Amid Progress on Broad-Spectrum Antiviral NV-387
NanoViricides will participate in the D. Boral Capital Global Conference, highlighting its clinical-stage antiviral drug NV-387 and its potential to treat multiple viral infections including RSV, COVID, and Monkeypox.
Annovis Bio CEO to Present Multi-Protein Approach to Alzheimer's at Fierce Biotech Week 2026
Annovis Bio CEO will present the company's multi-protein targeting strategy for Alzheimer's disease at Fierce Biotech Week 2026, highlighting buntanetap's Phase 3 trial.
Tonix Pharmaceuticals Secures GPO Agreement Covering 35 Million Lives for TONMYA Fibromyalgia Treatment
Tonix Pharmaceuticals announced a group purchasing organization agreement effective May 1, 2026, covering approximately 35 million U.S. commercial lives for its FDA-approved non-opioid fibromyalgia treatment TONMYA, expanding patient access.
Oragenics Advances Phase IIa Trial for Concussion Treatment, Targeting Data Readout by 2026
Oragenics Inc. is actively enrolling patients at a second site in its Phase IIa trial for ONP-002, a potential first-in-class treatment for concussion, with a data readout expected by end of 2026.
CNS Pharmaceuticals Raises $22.5 Million to Advance Pipeline and Corporate Strategy
CNS Pharmaceuticals announced a $22.5 million private placement with institutional investors to fund asset acquisition and working capital, signaling a strategic push to expand its pipeline.
NanoViricides Gains FDA Orphan Drug Designation for Measles Drug NV-387 Amid Global Outbreaks
NanoViricides received FDA Orphan Drug Designation for its broad-spectrum antiviral NV-387 to treat measles, offering incentives and supporting regulatory advancement as global cases rise.
Carmed Pharmaceuticals Launches 'Farkındayım' Initiative Ahead of U.S. Expansion
Carmed Pharmaceuticals launches a social impact initiative where digital engagement with music and video directly funds animal welfare, signaling a purpose-driven brand strategy as it expands into the U.S. market.
Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Alignment with Executive Order on Mental Health
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while reaffirming the collaboration's support for Phase 3 recruitment in major depressive disorder and alignment with a recent executive order on mental health treatments.
BioVersys Shareholders Approve All Board Proposals, Including New Board Member and Compensation Packages
BioVersys AG announced that shareholders approved all board proposals at its annual general meeting, including the re-election of directors and election of a new board member, as the company advances its lead antibiotic candidate into Phase 3 trials.
Oncotelic Therapeutics Advances AI and Robotics Platform Toward Initial Commercial Deployment
Oncotelic Therapeutics reports progress on its proprietary AI platform and robotics integration, aiming to improve efficiency and compliance in pharmaceutical development and manufacturing.
Telomir Pharmaceuticals Gains FDA Clearance for Telomir-Zn Phase 1/2 Trial in Triple-Negative Breast Cancer
Telomir Pharmaceuticals announced FDA IND clearance for Telomir-Zn to treat advanced triple-negative breast cancer, allowing a Phase 1/2 trial to proceed and marking a key step toward clinical development.
Tonix Pharmaceuticals Advances Lyme Disease Prevention with Phase 1 Data and Plans for Phase 2 Study
Tonix Pharmaceuticals reported Phase 1 data for its Lyme disease prevention candidate TNX-4800 and announced plans for an adaptive Phase 2 field study, highlighting the unmet need for prophylactic options in the U.S.
Lantern Pharma Expands predictBBB Platform into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), enabling real-time molecular intelligence for drug discovery, which could accelerate development and reduce costs.
LakeShore Biopharma Amends Merger Agreement, Slashes Share Consideration to $0.066 in Going-Private Deal
LakeShore Biopharma has amended its merger agreement to take the company private at a reduced equity value of $2.7 million, offering $0.066 per share after a revised proposal from the buyer group.
Earth Science Tech Positions Itself for Telehealth's Next Phase with Integrated Platform
Earth Science Tech Inc. is aligning with the evolution of telehealth from simple video visits to a comprehensive care model through its integrated platform that combines telemedicine, compounding pharmaceuticals, and patient services.
Telomir Pharmaceuticals Closes TELI Acquisition, Secures Global Rights to Lead Drug Candidate
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, obtaining sole global rights to Telomir-1, a drug aimed at treating advanced breast cancer and targeting aging-related diseases, with a $1 million upfront payment and up to $4 million in milestones.
Scinai Immunotherapeutics Raises $2.61M to Expand CDMO Platform and Advance Pipeline
Scinai Immunotherapeutics announced a $2.61 million private placement and warrant inducement, with proceeds supporting its CDMO expansion and immunotherapy pipeline.
Oncotelic Therapeutics Featured in NetworkNewsAudio Editorial Highlighting How Late-Stage Drug Pipelines Drive Valuation in Biotech
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a NetworkNewsAudio editorial that explores how advancing drug pipelines, particularly those near commercialization, create significant value in biopharma, directly relevant to Oncotelic's oncology-focused pipeline.
Oncotelic Therapeutics Highlights Partnership Strategy to Advance Pipeline and Boost Shareholder Value
Oncotelic Therapeutics updates its partnership-driven strategy, citing a $249 million valuation boost from its GMP Biotechnology joint venture and plans for further collaborations to advance its oncology pipeline efficiently.
Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR 2026, Highlighting Potential in Gastric Cancer and Immunotherapy
Tonix Pharmaceuticals announced new preclinical data for TNX-1700 and TNX-4700 at AACR 2026, showing potential in gastric cancer and as a BTLA-targeting immunotherapy, which could expand its oncology pipeline.
Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Newron Pharmaceuticals Shareholders Approve New Board Members at AGM 2026
Newron Pharmaceuticals' AGM 2026 approved the election of two independent directors, while extraordinary motions were postponed due to lack of quorum, highlighting shareholder dynamics.
Cingulate Advances ADHD Treatment Toward 2026 FDA Decision with Key Milestones
Cingulate Inc. progresses toward potential 2026 commercial launch of its ADHD treatment CTx-1301 following FDA acceptance of its New Drug Application and positive pediatric trial results, addressing a large market with unmet needs.